New drug combo for cervical cancer shows early promise, but trial halted
NCT ID NCT04651127
First seen Mar 27, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if the combination was safe and could shrink tumors, but results are too limited to draw firm conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Centre
Guangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab (an immunotherapy drug) and chidamide (a targeted drug)
What this could lead to
If it works, this combination could offer a new treatment option for advanced cervical cancer that has not responded to standard therapies.
What could go wrong
This was a very early, small trial (only 5 participants) that was terminated, so results are limited. The combination may cause significant side effects and may not prove effective in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.